Accelerated drug discovery and development platform Converge Bio Inc. today announced it has raised $25 million in early-stage funding to develop better drugs for pharmaceutical companies and open up opportunities in the industry using artificial intelligence.

Lilly and NVIDIA launch AI co-innovation lab to tackle drug discovery challenges.NVIDIA collaborates with Thermo Fisher to build

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The recent acquisition of Exscientia strengthens Recursion's ...

In this interview, Dr. Malika Bsibsi discusses the role of iPSC models in advancing neuroscience drug discovery, focusing on neurodegeneration, neuroinflammation, and innovative in vitro approaches. Could you start by introducing yourself and giving our ...

The new company combines Tahoe’s AI-powered target discovery engine with Alloy’s industry-leading ADC development capabilities to advance two first-in-class oncology programs built on deeply validated tumor targets.

Experience the forefront of pharmaceutical innovation as Labroots and the Drug Discovery and Development planning committee host the 9th Annual Drug Discovery & Development Virtual Event on February 18th, 2026. Join industry and academic leaders to explore ...

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), applauds the state of Utah which has become the first state in the United States to allow artificial intelligence systems to authorize prescription refills without direct physician involvement — a regulatory first that signals how AI is beginning to reduce healthcare costs,